Overview

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Status:
RECRUITING

Trial end date:
2030-03-31

Target enrollment:

Participant gender:

Summary

The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

Canadian Institutes of Health Research (CIHR)

Treatments:

Carboplatin
Docetaxel